GlassScriptPhysician profile
Abby L Koons
NPI 1558352682
$6,063.93
in general payments reported to CMS, 2019-2025
49 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $787 · 2023: $2,119 · 2024: $1,589 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,205 · Education: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.16 |
| Education | $836.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $738.33 | 2022-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $498.44 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Astellas Pharma US INC | $431.55 | 2022-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $421.81 | 2023-2025 | Enhertu, Lynparza |
| Seagen INC. | $389.00 | 2021-2023 | Padcev, Tukysa |
| Glaxosmithkline, LLC. | $336.19 | 2021-2025 | Zejula, Ojjaara, Blenrep |
| Pfizer INC. | $268.74 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $229.95 | 2021-2025 | Keytruda, Reblozyl, Welireg |
| Abbvie INC. | $209.11 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $176.52 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $172.91 | 2022-2024 | Opdivo |
| Daiichi Sankyo INC. | $157.05 | 2022-2025 | Enhertu, Injectafer |
| Sobi, INC | $151.76 | 2023-2024 | |
| Amgen INC. | $149.90 | 2021-2025 | Blincyto, Kyprolis, Vectibix |
| Gilead Sciences, INC. | $129.00 | 2021-2025 | Trodelvy |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $126.51 | 2022-2023 | |
| Genentech USA, INC. | $123.06 | 2023-2024 | Tecentriq, Venclexta, Alecensa |
| Jazz Pharmaceuticals INC. | $114.06 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.61 | 2025 | Fruzaqla |
| Celgene Corporation | $103.69 | 2023-2025 | Reblozyl, Pomalyst |
| Exelixis INC. | $86.95 | 2023-2025 | Cabometyx |
| Janssen Pharmaceuticals, INC | $74.37 | 2023-2024 | Xarelto |
| Incyte Corporation | $72.77 | 2022-2024 | Monjuvi, Jakafi |
| Regeneron Healthcare Solutions, INC. | $71.64 | 2022-2024 | Libtayo |
| Beone Medicines USA, INC. | $68.94 | 2025 | Brukinsa |
| Lilly USA, LLC | $55.20 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $52.71 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Tersera Therapeutics LLC | $46.98 | 2024 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $43.99 | 2023 | Imbruvica |
| Adaptive Biotechnologies Corporation | $42.03 | 2024-2025 | Clonoseq |
| Pharmaessentia USA Corporation | $33.87 | 2023 | Besremi |
| Acrotech Biopharma INC. | $31.15 | 2024 | Beleodaq |
| Geron Corporation | $31.02 | 2025 | Rytelo |
| Taiho Oncology, INC. | $29.02 | 2023-2025 | |
| Kyowa Kirin, INC. | $26.79 | 2022-2023 | Poteligeo |
| Inari Medical, INC. | $24.82 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pharming Healthcare, INC. | $24.63 | 2023 | Ruconest |
| Cti Biopharma Corp. | $22.86 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.77 | 2025 | Onivyde, Somatuline Depot |
| Argenx US, INC. | $21.62 | 2025 | Vyvgart Hytrulo |
| Pharmacosmos Therapeutics INC. | $18.98 | 2022 | |
| Genmab U.S., INC. | $18.07 | 2022 | |
| Servier Pharmaceuticals LLC | $16.90 | 2023 | |
| Tempus Ai, INC | $15.62 | 2024 | |
| Foundation Medicine, INC. | $15.29 | 2023 | |
| Kite Pharma, INC. | $15.11 | 2022 | |
| Beigene USA, INC. | $13.66 | 2022 | |
| Coherus Oncology, INC. | $13.15 | 2023 | |
| Array Biopharma INC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Koons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.